The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early rebiopsy to identify mechanisms and biomarkers of tumor cell survival following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.
 
Caroline Elizabeth McCoach
Honoraria - ARIAD
 
Dan Merrick
Honoraria - ARIAD
 
Dara L. Aisner
Honoraria - ARIAD
 
Paul A. Bunn
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Lilly; Merck; Merck Serono; Merrimack; Novartis; Pfizer; Puma Biotechnology
 
D. Ross Camidge
Honoraria - ARIAD
 
Dexiang Gao
No Relationships to Disclose
 
Kimi Kondo
Stock and Other Ownership Interests - Merck
Honoraria - ARIAD
 
Robert Charles Doebele
Honoraria - AstraZeneca; Clovis Oncology; Loxo; OxOnc; Pfizer
Consulting or Advisory Role - Array BioPharma; Lilly; Loxo; OxOnc; Pfizer; Pfizer
Research Funding - Abbott Molecular; Loxo; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Licensing Fees for Biologic Material from Ariad (Inst); Licensing Fees for Biologic Material from Blueprint Medicines (Inst); Licensing Fees for Biologic Material from Chugai (Inst); Licensing Fees for Biologic Materials from GVKbio; Licensing Fees for Biologic Materials from Loxo Oncology (Inst); Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495
Travel, Accommodations, Expenses - Ignyta